The study (completed) demonstrated the connection between uPAR-PET imaging and invasive biopsies. The study supports the idea, that uTRACE® may be used as a non-invasive biopsy for risk stratification
Curasight's Pipeline
Ongoing and completed Nuclear Medicine studies addresses a number of significant unmet diagnostic and medical needs. All completed and ongoing phase II clinical trials are investigator-initiated.
In short: phases of clinical research studies
Clinical trials testing potential medical products are commonly classified into four phases:
- Pre-clinical: Testing in non-human subjects to gather efficacy, toxicity and pharmacokinetic information.
- Phase I: Dose-ranging on 20–100 human volunteers to determine whether the product is safe to check for efficacy.
- Phase II: Testing of drug on 100-300 participants to assess efficacy and side effects .
- Phase III: Testing of drug on 300-3,000 participants to assess efficacy, effectiveness and safety.
If the product successfully passes through these four phases, it will usually be approved by the national regulatory authority for use in the general population.
(Source: Wikipedia)
In the last phase of Curasight’s pipeline – Product – Curasight partners with someone who will handle the global distribution of the product.
Diagnostics
Prostate cancer: The study (completed) demonstrated the connection between uPAR-PET imaging and invasive biopsies. The study supports the idea, that uTRACE® may be used as a non-invasive biopsy for risk stratification
Breast cancer: The study (completed) investigated the value of uPAR-PET in staging of breast cancer.
Brain cancer: The study (ongoing) investigates the uptake and diagnostic abilities of uPAR-PET in brain cancer.
Lung cancer: The study (ongoing) investigates the uptake of uPAR-PET in lung cancer and its prognostic value.
Bladder cancer: The study was discontinued prematurely for technical reasons due to high activity in the urine in the bladder making discrimination between cancer in the bladder wall and the bladder impossible.
Oral and Head and Neck cancer: The studies (ongoing) investigate the prognostic value of uPAR-PET in these cancer types.
Neuroendocrine tumors: The study (ongoing) investigate the uptake of uPAR-PET tracer in neuroendocrine tumors and the ability to predict prognosis.
Therapy
Prostate: The study demonstrated in a mouse model with human prostate cancer that 177Lu-DOTA-AE105 (uTREAT®) reduced the number of animals developing bone metastases to approximately half of that seen in non-treated animals.
Colorectal cancer: The study demonstrated in a mouse model with implanted human colorectal cancer (HT-29 cell line) that tumor growth was inhibited by 177Lu-DOTA-AE105 (uTREAT®).
Brain cancer: Ongoing studies sponsored by Curasight on uPAR-targeted radionuclide therapy. Positive biodistribution data obtained.
Product
preclinical
Phase 1
Phase 2
Phase 3
uTRACE®
uTREAT®
Prostate cancer
Prostate Cancer
Close
Breast cancer
Breast Cancer
Close
The study (completed) investigated the value of uPAR-PET in staging of breast cancer.
Brain cancer
Brain Cancer
Close
The study (ongoing) investigates the uptake and diagnostic abilities of uPAR-PET in brain cancer.
Lung cancer
Lung Cancer
Close
The study (ongoing) investigates the uptake of uPAR-PET in lung cancer and its prognostic value.
Bladder cancer
Bladder Cancer
Close
The study was discontinued prematurely for technical reasons due to high activity in the urine in the bladder making discrimination between cancer in the bladder wall and the bladder impossible.
Oral cancer
Oral Cancer
Close
The studies (ongoing) investigate the prognostic value of uPAR-PET in these cancer types.
Head & Neck cancer
Head & Neck Cancer
Close
The studies (ongoing) investigate the prognostic value of uPAR-PET in these cancer types.
Neuroendocrine
Neuroendocrine
Close
The study (ongoing) investigate the uptake of uPAR-PET tracer in neuroendocrine tumors and the ability to predict prognosis.
Prostate
Prostate
Close
The study demonstrated in a mouse model with human prostate cancer that 177Lu-DOTA-AE105 (uTREAT®) reduced the number of animals developing bone metastases to approximately half of that seen in non-treated animals.
Colorectal
Colorectal Cancer
Close
The study demonstrated in a mouse model with implanted human colorectal cancer (HT-29 cell line) that tumor growth was inhibited by 177Lu-DOTA-AE105 (uTREAT®).
Brain cancer
2020/2022
Brain Cancer
Close
Ongoing studies sponsored by Curasight on uPAR-targeted radionuclide therapy. Positive biodistribution data obtained.
Programmes
Curasight is focused on addressing the need for improved diagnose of Prostate cancer and building on its foundation of pioneering research and development within uPAR-PET Imaging.
Our clinical development efforts include a program to develop a first-in-class uPAR-PET imaging ligand which is currently in phase II. We believe that our uPAR-PET ligands have the potential to provide physicians with improved non-invasive and cost-effective options to help diagnose and evaluate prostate cancer disease.